Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Introduction: Behavioural and psychological symptoms of dementia (BPSD) include agitation and aggression in people with dementia. BPSD is common on inpatient psychogeriatric units and may prevent individuals from living at home or in residential/nursing home settings. Several drugs and non-pharmacological treatments have been shown to be effective in reducing behavioural and psychological symptoms of dementia. Algorithmic treatment may address the challenge of synthesizing this evidence-based knowledge. Methods: A multidisciplinary team created evidence-based algorithms for the treatment of behavioural and psychological symptoms of dementia. We present drug treatment algorithms for agitation and aggression associated with Alzheimer’s and mixed Alzheimer’s/vascular dementia. Drugs were appraised by psychiatrists based on strength of evidence of efficacy, time to onset of clinical effect, tolerability, ease of use, and efficacy for indications other than behavioural and psychological symptoms of dementia. Results: After baseline assessment and discontinuation of potentially exacerbating medications, sequential trials are recommended with risperidone, aripiprazole or quetiapine, carbamazepine, citalopram, gabapentin, and prazosin. Titration schedules are proposed, with adjustments for frailty. Additional guidance is given on use of electroconvulsive therapy, optimization of existing cholinesterase inhibitors/memantine, and use of pro re nata medications. Conclusion: This algorithm-based approach for drug treatment of agitation/aggression in Alzheimer’s/mixed dementia has been implemented in several Canadian Hospital Inpatient Units. Impact should be assessed in future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 2×
“…a meta-analysis (Cheung and Stapelberg, 2011) combining five randomized trials reported a statistically significant effect relative to placebo on neuropsychiatric symptoms (Neuropsychiatric Inventory scores (Cummings et al., 1994)) and overall improvement (Clinical Global Impression (CGI) scores).”
MethodThe global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 2×
“Over 35 m people have dementia worldwide (Prince et al., 2013) and the prevalence is anticipated to double every 20 years (Ferri et al., 2005).”
BackgroundLyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 1×
“Up to 80% of patients with dementia present with BPSD at some stage of their illness (Lyketsos et al., 2002).”
BackgroundSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“A further concern is the reported increased risk of stroke and mortality associated with atypical antipsychotics (Schneider et al., 2005).”
BackgroundSchneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 4×
“…quetiapine ranked well for time to onset of effect with CGI change score reported to be significantly greater than placebo after one week (Zhong et al., 2007), tolerability, and its evidence of efficacy in other disorders such as Generalized Anxiety Disorder (for review see Baldwin et al., 2014).”
BackgroundSelf-citationPrevalence of psychiatric disorders among older adults in long-term care homes: a systematic review
Seitz, D., Purandare, N., & Conn, D. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210000608 · Cited by 592 · cited 1×
“The presence of BPSD is associated with impaired quality of life, and increased rate of institutionalization and cost of care with many people having to live in residential care settings such as long-term care homes (Seitz et al., 2010; Zuidema et al., 2010).”
BackgroundEffect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“…favor of the inclusion of citalopram is the recent successful placebo-controlled randomized trial known as “CitAD” in which citalopram titrated to a target of 30 mg/day was effective in reducing BPSD symptoms (Porsteinsson et al., 2014) and three previous trials (Pollock et al., 1997, 2002, 2007).”
MethodSelf-citation
Cited by
Brown, E. E., Kumar, S., Rajji, T. K., Pollock, B. G., & Mulsant, B. H. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.04.010 · Cited by 483
Self-citationManagement of Behavioral and Psychological Symptoms of Dementia
Bessey, L. J., & Walaszek, A. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1049-5 · Cited by 288
Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00597-3 · Cited by 189
Teixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
Freedman, M., Binns, M. A., Serediuk, F., Wolf, M. U., Danieli, E., Pugh, B., Galet, D., Abdellah, E., Teleg, E., Halper, M., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-215403 · Cited by 7
Metadata
- Authors
- Davies, S. J., Burhan, A. M., Kim, D., Gerretsen, P., Graff-Guerrero, A., Woo, V. L., Kumar, S., Colman, S., Pollock, B. G., Mulsant, B. H., & Rajji, T. K.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-01-17
- Volume
- 32
- Issue
- 5
- Pages
- 509-523
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2785062770
- Cited by
- 146
- References
- 23
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. https://app.cochat.ai/papers/10.1177/0269881117744996
- The paper
- Davies, S. J., Burhan, A. M., Kim, D., Gerretsen, P., Graff-Guerrero, A., Woo, V. L., Kumar, S., Colman, S., Pollock, B. G., Mulsant, B. H., & Rajji, T. K. (2018). Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117744996
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.